Aubree L. Gordon

This study evaluates antibody evasion and ACE2 receptor engagement of SARS-CoV-2 variant RW.1.1, finding reduced receptor binding but no increased serum resistance compared to other variants.

This study finds that young children have lower neutralizing antibody titers against BA.3.2.2 compared to adults, despite similar titers against dominant variants, suggesting age-related differences in susceptibility.

This study evaluates the effectiveness of LP.8.1-targeted mRNA vaccines in boosting neutralizing antibodies and reducing immune imprinting from ancestral SARS-CoV-2 strains.

This study identifies antibody epitopes on the hMPV F protein from children and shows their neutralizing activity and prophylactic efficacy in mice.

This study compares antibody evasion and receptor binding of SARS-CoV-2 subvariants, finding that LP.8.1.1 has high ACE2 affinity, while NB.1.8.1 and XFG show greater antibody evasion.

This study assesses whether 2025 COVID-19 vaccines need updating by testing neutralizing antibody titers against emerging variants in individuals vaccinated with KP.2-based mRNA vaccines.

This study evaluates the antibody evasion of SARS-CoV-2 subvariants KP.3.1.1 and XEC compared to their parental variants, finding increased resistance to neutralization by sera and antibodies targeting the spike protein.

This study tracks SARS-CoV-2 genetic diversity in Nicaragua from 2020 to 2022, showing lineage shifts and linking mutations to hospitalization rates.

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

This study examines how recurrent spike mutations in SARS-CoV-2 JN.1 sublineages affect immune evasion, ACE2 affinity, and infectivity, identifying growth advantages in specific sublineages.

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.